Clinical Trial

European Registry of Next Generation Imaging in Advanced Prostate Cancer

Study acronym: RING

Recruiting

Record status

This record was last updated March 11, 2025 (before its estimated December 23, 2025 completion). Its status may not reflect the trial's current state.

Summary

The RING study is a European registry collecting real-world data on advanced prostate cancer (APC) imaging. It aims to evaluate the role of next-generation imaging (NGI), such as PET/CT and whole-body MRI, in detecting and monitoring the disease compared to conventional imaging. Men aged 18 or older with histologically confirmed prostate cancer are eligible to participate in the study if they require imaging to assess potential metastases, either at diagnosis or after relapse and sign a consent form. Patients will receive standard care with no experimental treatments. Imaging and treatment decisions will follow routine clinical practice. Data will be collected from medical records and analysed for research. This study will help doctors understand when NGI should be used, how it affects treatment decisions, and its impact on patient outcomes.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-03-04.

Trial Details

NCT Number	NCT06866782
Lead Sponsor	Fundacio Puigvert Collaborators: European Association of Urology Research Foundation, Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD, European Association of Urology - Section of Urological Imaging, Johnson & Johnson, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Conditions	Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer (mPC)
Enrollment	600 participants
Start Date	2024-09-17
Primary Completion	2025-12-23 (estimated)
Study Completion	2026-12-23 (estimated)
Updated on ClinicalTrials.gov	2025-03-11